Literature DB >> 23650406

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.

Christopher J Anker1, Antoni Ribas, Allie H Grossmann, Xinjian Chen, Krishna K Narra, Wallace Akerley, Robert H I Andtbacka, Robert Dirk Noyes, Dennis C Shrieve, Kenneth F Grossmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23650406     DOI： 10.1200/JCO.2012.44.7755

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  23 in total

1.  Targeting precision medicine toxicity: recent developments.

Authors:  Gordon Mallarkey; Arduino A Mangoni
Journal:  Ther Adv Drug Saf       Date:  2015-02

2.  Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: A case report.

Authors:  Dinu Stefan; Hosni Popotte; Andreea Raluca Stefan; Audrey Tesniere; Aurélie Tomaszewski; Paul Lesueur; Jean-Louis Habrand; Laurence Verneuil
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

3.  Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.

Authors:  David A Liebner; Steven A Walston; Robert Cavaliere; Ciaran J Powers; Eric Sauvageau; Norman L Lehman; Hasel Wayne Slone; Meng Xu-Welliver; Fen Xia; Kari L Kendra
Journal:  Melanoma Res       Date:  2014-04       Impact factor: 3.599

4.  BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.

Authors:  Panagiotis Mastorakos; Zhiyuan Xu; James Yu; Judith Hess; Jack Qian; Ajay Chatrath; Davis G Taylor; Douglas Kondziolka; Ronald Warnick; Veronica Chiang; Jason Sheehan
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

5.  [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].

Authors:  R Gutzmer; J C Hassel; K C Kähler; C Loquai; R Mössner; S Ugurel; L Zimmer; Für Komitee Kutane Nebenwirkungen Ado der das Ado
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

6.  Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy.

Authors:  Ricarda Merten; Markus Hecht; Marlen Haderlein; Luitpold Distel; Rainer Fietkau; Lucie Heinzerling; Sabine Semrau
Journal:  Strahlenther Onkol       Date:  2014-06-26       Impact factor: 3.621

Review 7.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

8.  Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports.

Authors:  B Schulze; M Meissner; M Wolter; C Rödel; C Weiss
Journal:  Strahlenther Onkol       Date:  2013-12-22       Impact factor: 3.621

Review 9.  Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Authors:  Sarah J Welsh; Pippa G Corrie
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

10.  BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.

Authors:  Kirtesh R Patel; Mudit Chowdhary; Jeffrey M Switchenko; Ragini Kudchadkar; David H Lawson; Richard J Cassidy; Roshan S Prabhu; Mohammad K Khan
Journal:  Melanoma Res       Date:  2016-08       Impact factor: 3.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.